

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The ongoing MOUNTAINEER-02 trial is investigating which of the following HER2-directed agents in combination with ramucirumab and paclitaxel for patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma?

 - a. Pertuzumab/tucatinib
 - b. Tucatinib/trastuzumab**
 - c. Pertuzumab/trastuzumab
2. In the recent presentation at ESMO 2020 by Boku and colleagues, which of the following outcomes was reported from the Phase III portion of the ATTRACTION-4 trial of nivolumab or placebo in combination with either SOX (S-1 with oxaliplatin) or capecitabine/oxaliplatin for patients with previously untreated or recurrent HER2-negative gastric or GEJ cancer?

 - a. A significant improvement in only progression-free survival (PFS) with the addition of nivolumab**
 - b. A significant improvement in only overall survival (OS) with the addition of nivolumab
 - c. A significant improvement in both PFS and OS with the addition of nivolumab
 - d. No significant difference in either PFS or OS between the study arms
3. Which of the following factors is significantly associated with longer OS for patients with previously treated metastatic colorectal cancer (mCRC) who receive TAS-102 or regorafenib?

 - a. Baseline white blood cell count higher than $8 \times 10^9/L$
 - b. An ECOG performance status of 1 or higher
 - c. Time of 3 months or less from diagnosis of mCRC
 - d. Time of at least 24 months from diagnosis of mCRC**
4. Which of the following statements is true about the results of the Phase II DESTINY-CRC01 trial of the antibody-drug conjugate trastuzumab deruxtecan for patients with HER2-expressing mCRC refractory to standard therapies?

 - a. Response was observed only in patients without prior exposure to anti-HER2 therapy
 - b. Response was observed only in patients with prior exposure to anti-HER2 therapy
 - c. Response was observed in patients regardless of prior exposure to anti-HER2 therapy**